

BIOVAXYS

BioVaxys Announces Revocation of Cease Trade Order and Expansion of Cancer Vaccine Platform Patent Portfolio

VANCOUVER, BC, November 23rd 2023 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that a Failure to File Cease Trade Order (“FFCTO”) issued October 5th, 2023, by the Ontario Securities Commission has been revoked as of November 22, 2023, and Canadian trading in BioVaxys stock (CSE:BIOV) will resume. The FFCTO was issued following the Company’s delay in filing the periodic disclosure of its financial statement and analysis for the quarter ending July 31, 2023 to the Canadian regulatory authorities; all disclosure documents for that quarter have been submitted.

In other news, The Company’s US Patent Application #18/557,655 entitled BIHAPTENIZED AUTOLOGOUS VACCINES AND USES THEREOF was submitted October 27th, 2023, with the United States patent & Trademark Office (“USPTO”). This application was filed as a US national stage of the previously filed International Application. BioVaxys is continuing additional national phase filings for its bihaptened vaccine platform outside the US, with additional submissions upcoming.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceutical company based in Vancouver, Canada, is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary *HapTenix*® 'neoantigen' tumor cell construct platform for treating refractive late stage ovarian cancer, and is also the exclusive US distributor of a portfolio of OTC female reproductive health products currently marketed in the EU from Barcelona-based Procure Health Iberia. BioVaxys is also exploring vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its *HapTenix*® platform through academic and other collaborations.

ON BEHALF OF THE BOARD

Signed “James Passin”

James Passin, CEO
+1 646 452 7054

Cautionary Statements Regarding Forward Looking Information

*This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved.. **There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.***

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys’ vaccines will not prove to be effective and/or will not receive the required regulatory approvals. With regards to BioVaxys’ business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.